PL432015A1 - Sposób oceny skuteczności leczenia chemioterapeutycznego raka płuca, panel biomarkerów metabolicznych i zestaw do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca - Google Patents

Sposób oceny skuteczności leczenia chemioterapeutycznego raka płuca, panel biomarkerów metabolicznych i zestaw do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca

Info

Publication number
PL432015A1
PL432015A1 PL432015A PL43201519A PL432015A1 PL 432015 A1 PL432015 A1 PL 432015A1 PL 432015 A PL432015 A PL 432015A PL 43201519 A PL43201519 A PL 43201519A PL 432015 A1 PL432015 A1 PL 432015A1
Authority
PL
Poland
Prior art keywords
lung cancer
effectiveness
panel
treatment
metabolic biomarkers
Prior art date
Application number
PL432015A
Other languages
English (en)
Other versions
PL241608B1 (pl
Inventor
Ewa PARFIENIUK
Adam KRĘTOWSKI
Michał CIBOROWSKI
Jacek NIKLIŃSKI
Ewa SIERKO
Joanna KIŚLUK
Karolina PIETROWSKA
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL432015A priority Critical patent/PL241608B1/pl
Priority to PCT/PL2019/000114 priority patent/WO2021107792A1/en
Publication of PL432015A1 publication Critical patent/PL432015A1/pl
Publication of PL241608B1 publication Critical patent/PL241608B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem wynalazku jest sposób oceny skuteczności leczenia chemioterapeutycznego u osobnika z rakiem płuca, w którym w próbce od osobnika z rakiem płuca przed rozpoczęciem leczenia chemioterapeutycznego oznacza się ilościowo panel biomarkerów metabolicznych, następnie w próbce od tego samego osobnika po co najmniej dwóch cyklach leczenia chemioterapeutycznego oznacza się ilościowo ponownie ten panel biomarkerów metabolicznych, porównuje się uzyskane wyniki i na podstawie uzyskanego wyniku porównania określa się status skuteczności leczenia chemioterapeutycznego u osobnika. Przedmiotem wynalazku jest także panel biomarkerów metabolicznych, panel biomarkerów metabolicznych do zastosowania w diagnostyce in vitro, panel biomarkerów metabolicznych do zastosowania do monitorowania in vitro skuteczności leczenia chemioterapeutycznego raka płuca oraz zestaw do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca.
PL432015A 2019-11-29 2019-11-29 Diagnostyczny panel biomarkerów metabolicznych do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca PL241608B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL432015A PL241608B1 (pl) 2019-11-29 2019-11-29 Diagnostyczny panel biomarkerów metabolicznych do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca
PCT/PL2019/000114 WO2021107792A1 (en) 2019-11-29 2019-11-30 Method for assessing effectiveness of chemotherapeutic treatment of lung cancer, panel of metabolic biomarkers and kit for monitoring effectiveness of chemotherapeutic treatment of lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432015A PL241608B1 (pl) 2019-11-29 2019-11-29 Diagnostyczny panel biomarkerów metabolicznych do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca

Publications (2)

Publication Number Publication Date
PL432015A1 true PL432015A1 (pl) 2021-05-31
PL241608B1 PL241608B1 (pl) 2022-11-07

Family

ID=69375979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432015A PL241608B1 (pl) 2019-11-29 2019-11-29 Diagnostyczny panel biomarkerów metabolicznych do monitorowania skuteczności leczenia chemioterapeutycznego raka płuca

Country Status (2)

Country Link
PL (1) PL241608B1 (pl)
WO (1) WO2021107792A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115266985A (zh) * 2022-07-29 2022-11-01 国家烟草质量监督检验中心 一种基于uhplc-qtof-ms的喉癌患者血清脂质组学检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109946390B (zh) * 2017-12-20 2022-05-06 上海市生物医药技术研究院 一种肺癌诊断标志物组合及应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115266985A (zh) * 2022-07-29 2022-11-01 国家烟草质量监督检验中心 一种基于uhplc-qtof-ms的喉癌患者血清脂质组学检测方法
CN115266985B (zh) * 2022-07-29 2023-12-22 国家烟草质量监督检验中心 一种基于uhplc-qtof-ms的喉癌患者血清脂质组学检测方法

Also Published As

Publication number Publication date
WO2021107792A1 (en) 2021-06-03
PL241608B1 (pl) 2022-11-07

Similar Documents

Publication Publication Date Title
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
NZ706155A (en) Use of markers in the identification of cardiotoxic agents
Berry Models for mesothelioma incidence following exposure to fibers in terms of timing and duration of exposure and the biopersistence of the fibers
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
PH12017502200A1 (en) Methods of diagnosing and treating cancer
MX2019001147A (es) Lamina de acerro de alta resistencia y metodo para producir la misma.
BR112015020329A2 (pt) aço com resistência a desgaste aumentada e métodos para a produção do mesmo
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
WO2024015628A3 (en) Organ aging biomarkers derived from the plasma proteome
BR112023000892A2 (pt) Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
GB2552271A (en) A method for diagnosing lung cancer
Ahuja et al. Occupational lung disease
PL435967A1 (pl) Zestaw biomarkerów miRNA do diagnostyki raka jajnika, sposób diagnostyki in vitro raka jajnika, zastosowania zestawu biomarkerów miRNA oraz test do diagnostyki in vitro raka jajnika
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
MX2021009281A (es) Metodos de deteccion de legionella.
BR112018015487A2 (pt) método para diagnosticar um indivíduo que sofre de câncer ou doença metastática, kit para diagnosticar um indivíduo que sofre de câncer ou doença metastática, método ou kit, uso de um peptídeo de seq id no: 3, ou um fragmento ou variante da mesma, inibidor da síntese e/ou atividade de um peptídeo de seq id no: 3, inibidor para uso, composição farmacêutica, processo para produzir a composição farmacêutica e método de triagem de um composto
EP4328324A3 (en) Methods of diagnosing epilepsy
EP3599288A3 (en) Diagnosis and treatment of psoriatic arthritis
KR102235718B9 (ko) 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
Cozza et al. 6-minute walking test (6MWT) in patients with silicosis